Dr. Berrondo is a scientist, software engineer, product, and operations executive with
impeccable execution, and a passion for advancing medicine.

She is the co-founder and CEO of Sekhmet Partners, leading the efforts around fundraising, portfolio sourcing, and exit strategy. In addition, she is co-founder and CEO of Macromoltek, a company that is building the first-in-class in silico, rational antibody design technology and went through the prestigious Y Combinator accelerator in Winter of 2018.

She is responsible for all activities in business development, therapeutic program discovery, and development. She is responsible for multiple pharma and biotech partnerships and has successfully licensed the company’s antibodies to partners worldwide. In 2022, she co-founded Brazen Capital, an investment fund devoted to supporting underrepresented populations in biomedical research.

Dr. Berrondo is an active mentor to both students and new entrepreneurs and founders.
Her expertise lies in applying computational approaches to complex scientific problems and
bringing projects to fruition through strategic planning. She is active in the science and
women-entrepreneurship community around Austin and beyond. She first began working on the drug discovery process in high school, where she used computational modeling to predict biological processes.

After receiving a BS from RPI, Dr. Berrondo pursued her doctoral degree in Chemical Engineering from Johns Hopkins University. She received the NIH’s prestigious Ruth L. Kirschstein fellowship to conduct her doctoral research on protein structure and function. Dr. Berrondo played a central role in developing the Rosetta protein modeling software and advanced the transformation of the software into a more scalable product. She was voted Austin Magazine’s Woman of the Year in 2013 and Austin startup Week’s Founder of the Year in 2015 before starting the Central Texas chapter of Women In Bio, which she led for 2 years.